The Galleri® Multi-Cancer Early Detection Test in Hackensack, NJ
Proactive Screening for Peace of Mind.
Early detection of cancer is the most effective way to improve treatment outcomes. While traditional screenings like mammograms and colonoscopies are vital, they only test for a handful of cancers.
Our Hackensack clinic now offers the Galleri Multi-Cancer Early Detection test which is a blood-based test designed to detect signals associated with over 50 different types of cancers from a single blood draw. Using advanced genomic analysis of cell-free DNA, the test can identify patterns that may suggest the presence of a cancer signal and often indicate where in the body that signal may have originated.
Book Galleri® Testing with Local New Jersey Board-Certified Physicians
Or call: 201-983-2582
Cancer Signal Origin Detection Accuracy *
Sensitivity to the Most Aggressive Cancer Types for Early Treatment *
Lowest False Positive Rate of Any Multi-Cancer Early Detection Test *
What is the Galleri® Test?
The Galleri® test is a first-of-its-kind screening tool that uses next-generation genomic sequencing to analyze your blood.
All cells, including cancer cells, shed DNA into the bloodstream. This cell-free DNA carries specific signals. The Galleri® test looks for the unique DNA signature shed by cancer cells to detect a cancer signal and predict where in the body it originates.
Why Choose the Galleri® Test for Cancer Screening?
Screens for 50+ Types of Cancer
Detects signals for difficult-to-diagnose cancers, including pancreatic, ovarian, esophageal, and liver cancer.
Simple Blood Draw
No fasting, radiation, or invasive procedures required.
High Accuracy
The test’s low false-positive rate reduces unnecessary anxiety.
Practical Diagnostics for Swift Treatment
If a cancer signal is found, the Galleri® test predicts the tissue or organ of origin with high accuracy to guide diagnostic next steps.
Who Is This Galleri® Test For?
The Galleri® test is recommended for adults with an elevated risk of cancer, specifically:
- Adults aged 50 or older
- Individuals with a family history of cancer or other risk factors (such as smoking)
- Anyone looking to complement their standard cancer screenings with a more comprehensive approach
Note: The Galleri® test does not replace recommended routine cancer screenings (like colonoscopies, mammograms, or PSA tests). It is intended to be used in addition to these routine tests.
The Galleri® Testing Process at Our Hackensack Clinic
Consultation is complementary
You will meet with our doctors to discuss your health history and determine if the Galleri® test is right for you.
Blood Draw
We can perform the blood tests in our office, or we can send you a requisition so you may complete testing at any Quest Diagnostics location nationwide.
Your Results
Galleri test results are typically available within 2–3 weeks after the blood draw
Answers to Your Galleri® Cancer Screening Test Questions
Does insurance cover the Galleri® test?
Currently, most insurance providers do not cover the Galleri® test as it is a new technology. We offer transparent pricing for the test. Please contact our office for current costs and payment options.
Is this test a replacement for a colonoscopy or mammogram?
No. The Galleri® test is a complement to standard screenings, not a replacement. You should continue to follow the screening schedule recommended by your healthcare provider.
How accurate is the Galleri® test?
In clinical studies, the Galleri® test demonstrated a very low false-positive rate. It is highly effective at detecting aggressive cancers that shed more DNA into the bloodstream.
Can I eat before my appointment?
Yes. The Galleri® test does not require fasting. You can eat and drink normally before your blood draw.
Do I need a prescription?
Yes. The Galleri® test requires a prescription from a licensed healthcare provider. Our team in Hackensack can provide the necessary consultation and prescription if you are eligible.
* Nabavizadeh N, et al. Safety and performance of MCED test in an intended-use population: initial results from the registrational PATHFINDER 2 study [proffered presentation]. ESMO Congress; 2025 Oct 17-21; Berlin.
* Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77
* https://grail.com/press-releases/grail-pathfinder-2-results-show-galleri-multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings/
Trusted Care. Proven Results.
Join patients choosing a smarter, proactive approach to modern medicine.
Or call: 201-983-2582